Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Acquires $20,250.00 in Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman bought 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The shares were acquired at an average price of $4.05 per share, for a total transaction of $20,250.00. Following the completion of the transaction, the chief executive officer directly owned 16,005 shares in the company, valued at approximately $64,820.25. This represents a 45.43% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Seth Lederman also recently made the following trade(s):

• On Thursday, August 27th, Seth Lederman purchased 2,000 shares of Tonix Pharmaceuticals stock. The stock was acquired at an average cost of $13.79 per share, with a total value of $27,580.00.

Tonix Pharmaceuticals Stock Down 7.1%

TNXP traded down $0.23 on Friday, hitting $3.01. The company had a trading volume of 1,924,597 shares, compared to its average volume of 1,025,831. The company has a market cap of $58.48 million, a PE ratio of -0.25 and a beta of 1.90. Tonix Pharmaceuticals Holding Corp. has a 12-month low of $2.90 and a 12-month high of $20.56. The business’s fifty day simple moving average is $7.72 and its 200 day simple moving average is $11.85.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Monday, November 9th. The company reported ($2.89) earnings per share for the quarter, missing the consensus estimate of ($2.39) by ($0.50). Tonix Pharmaceuticals had a negative return on equity of 80.97% and a negative net margin of 420.45%. The company had revenue of $17.23 million for the quarter, compared to the consensus estimate of $16.32 million. On average, analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -10.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on TNXP. Wall Street Zen downgraded Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Canaccord Genuity Group assumed coverage on Tonix Pharmaceuticals in a research report on Monday, October 26th. They issued a “buy” rating and a $18.00 price target for the company. Raymond James Financial restated a “strong-buy” rating on shares of Tonix Pharmaceuticals in a research report on Tuesday, October 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Monday, October 26th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Tonix Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $22.33.

Institutional Trading of Tonix Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in TNXP. Bank of New York Mellon Corp bought a new position in Tonix Pharmaceuticals in the 2nd quarter valued at $533,000. Bank of America Corp DE increased its stake in Tonix Pharmaceuticals by 101.1% in the first quarter. Bank of America Corp DE now owns 60,958 shares of the company’s stock worth $838,000 after purchasing an additional 30,644 shares during the period. Great Lakes Advisors LLC bought a new stake in shares of Tonix Pharmaceuticals during the second quarter worth $303,000. Empowered Funds LLC bought a new stake in shares of Tonix Pharmaceuticals during the third quarter worth $192,000. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of Tonix Pharmaceuticals during the second quarter worth $92,000. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes medicines for central nervous system disorders and pursues research programs in immunology, rare diseases and infectious diseases. Its product Tonmya (cyclobenzaprine hydrochloride sublingual tablets) received U.S. Food and Drug Administration approval in 2025 for the treatment of fibromyalgia in adults. The company also has a development pipeline that includes drug candidates and vaccine programs, including research targeting smallpox and mpox.